



Model List of Essential Medicines



Acenocoumarol [General information](#)

Section

Medicines affecting coagulation

Indications

Therapeutic equivalent to [warfarin](#) for [Other specified diseases of arteries or arterioles](#) Therapeutic equivalent to [warfarin](#) for [Venous thromboembolism](#) Therapeutic equivalent to [warfarin](#) for [Cerebral ischaemic stroke due to embolic occlusion](#) Therapeutic equivalent to [warfarin](#) for [Atrial fibrillation](#)



Apixaban [General information](#)

Section

Medicines affecting coagulation

Indications

Therapeutic equivalent to [dabigatran](#) for [Other specified atrial fibrillation](#) Therapeutic equivalent to [dabigatran](#) for [Venous thromboembolism](#)



Dabigatran [General information](#)

Section

Medicines affecting coagulation

- Oral > Solid: 110 mg; 150 mg

Indications

[Other specified atrial fibrillation](#) [Venous thromboembolism](#)



Dalteparin [General information](#)

Section

Medicines affecting coagulation

Indications

Therapeutic equivalent to [enoxaparin](#) for [Venous thromboembolism](#) Therapeutic equivalent to [enoxaparin](#) for [Acute ischaemic heart disease](#)



Desmopressin [General information](#)

Section

Medicines affecting coagulation

- Parenteral > General injections > IV: 4 µg per mL in 1 mL ampoule (acetate)
- Local > Nasal > Spray: 150 µg per actuation (acetate)

Indications

[Haemophilia A Von Willebrand disease](#)



Edoxaban [General information](#)

Section

Medicines affecting coagulation

Indications

Therapeutic equivalent to [dabigatran](#) for [Other specified atrial fibrillation](#) Therapeutic equivalent to [dabigatran](#) for [Venous thromboembolism](#)

Emicizumab [General information](#)

Section

Medicines affecting coagulation

- Parenteral > General injections > SC: 12 mg per 0.4 mL in vial; 30 mg per mL in mL vial; 60 mg per 0.4 mL in vial; 105 mg per 0.7 mL in vial; 150 mg per mL in vial; 300 mg per 2 mL in vial

Indications

[Haemophilia A](#)

Enoxaparin [General information](#)

Section

Medicines affecting coagulation

- Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule; 120 mg per 0.8 mL in ampoule

Indications

[Venous thromboembolism Acute ischaemic heart disease](#)

Heparin sodium [General information](#)

Section

Medicines affecting coagulation

- Parenteral > General injections > IV: 1000 IU per mL in 1 mL ampoule or vial; 20000 IU per mL in 1 mL ampoule or vial; 5000 IU per mL in 1 mL ampoule or vial

Indications

[Acute ischaemic heart disease Unstable angina Venous thromboembolism](#)

Nadroparin [General information](#)

Section

Medicines affecting coagulation

Indications

Therapeutic equivalent to [enoxaparin](#) for [Venous thromboembolism](#) Therapeutic equivalent to [enoxaparin](#) for [Acute ischaemic heart disease](#)

Phytomenadione [General information](#)

Section

Medicines affecting coagulation

- Parenteral > General injections > IV: 10 mg per mL in ampoule; 1 mg per mL in ampoule; 2 mg per 0.2 mL in ampoule mixed micelle solution; 10 mg per mL in ampoule mixed micelle solution; 1 mg per 0.5 mL in ampoule
- Oral > Solid > tablet: 5 mg tablet

Indications

[Haemorrhagic disorder due to circulating anticoagulants or coagulation factors inhibitors Haemorrhagic or haematological disorders of fetus or newborn](#)

Protamine sulfate [General information](#)

Section

Medicines affecting coagulation

- Parenteral > General injections > IV: 10 mg per mL in 5 mL ampoule or vial

Indications

[Haemorrhagic disorder due to circulating anticoagulants or coagulation factors inhibitors](#)

Rivaroxaban [General information](#)

Section

Medicines affecting coagulation

Indications

Therapeutic equivalent to [dabigatran](#) for [Other specified atrial fibrillation](#) Therapeutic equivalent to [dabigatran](#) for [Venous thromboembolism](#)

Tranexamic acid [General information](#)

Section

Medicines affecting coagulation

- Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule

Indications

[Haemorrhage, not elsewhere classified](#)

Warfarin [General information](#)

Section

Medicines affecting coagulation

- Oral > Solid > tablet: 5 mg (scored) (sodium); 1 mg (scored) (sodium); 2 mg (scored) (sodium); 0.5 mg (scored) (sodium); 3 mg (scored) (sodium)
- Oral > Solid > tablet: 5 mg (scored) (sodium); 1 mg (scored) (sodium); 2 mg (scored) (sodium); 0.5 mg (scored) (sodium); 3 mg (scored) (sodium)

Indications

[Other specified diseases of arteries or arterioles](#) [Venous thromboembolism](#) [Cerebral ischaemic stroke due to embolic occlusion](#) [Atrial fibrillation](#)